ASCO 2021 | Advances in esophageal cancer and unanswered questions

John V. Reynolds, MD, St. James’s Hospital and Trinity College Dublin, Dublin, Ireland, addresses the progress that has been done in esophageal cancer research over the last 20 years through randomized clinical trials along with the advent of adjuvant immunotherapy which was shown to be well tolerated in esophageal cancer patients. Prof. Reynolds outlines that despite advancements in esophageal cancer research, a key question that needs to be further addressed in future trials is whether patients should receive chemotherapy after surgery and if that is the case, to what extent chemotherapy after surgery should be the same as the chemotherapy that the patient received prior surgery irrespective of what its outcomes were. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.